Grant: Operating Grant: COVID-19 - Therapeutics
University of Toronto
$535,318.00
Neutralizing Antibodies as SARS-CoV-2 Therapeutics
FY 2019-20
Summary
Three highly virulent coronaviruses - SARS-CoV, MERS-CoV and SARS-CoV-2 - have crossed species barriers to infect humans since 2003. SARS-CoV-2 is responsible for COVID-19, a disease that arose in Wuhan China in December of 2019. The virus has infected over 64,000 people and caused 1380 deaths and the World Health Organization has declared it a public health emergency of international concern. Although drastic measures are being taken to contain SARS-CoV-2, there is an urgent need for new therapeutics to combat this virus and reduce its spread. In this work we will develop therapeutics based on human antibodies that can be used in the treatment of COVID-19.
Department
Program
Operating Grant: COVID-19 - Therapeutics
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
422720
Name
Rini James M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canadian 2019 Novel Coronavirus (2019-nCoV) Rapid Research
Projecttitle
Neutralizing Antibodies as SARS-CoV-2 Therapeutics
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$535,318
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 - Therapeutics
Keyworddelim
Antibodies; Coronavirus; Covid-19; S-Protein; Sars-Cov-2; Therapeutic Antibodies
Abstract
Three highly virulent coronaviruses - SARS-CoV, MERS-CoV and SARS-CoV-2 - have crossed species barriers to infect humans since 2003. SARS-CoV-2 is responsible for COVID-19, a disease that arose in Wuhan China in December of 2019. The virus has infected over 64,000 people and caused 1380 deaths and the World Health Organization has declared it a public health emergency of international concern. Although drastic measures are being taken to contain SARS-CoV-2, there is an urgent need for new therapeutics to combat this virus and reduce its spread. In this work we will develop therapeutics based on human antibodies that can be used in the treatment of COVID-19.
Competitiondate
202002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Rini, James M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $535,318~ $0~
